Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
Profound Medical (NASDAQ:PROF) announced that The Hong Center Scottsdale, led by Dr. Y. Mark Hong, reached a world-first milestone of 200 independent TULSA Procedures performed by a urologist without radiologist involvement on Nov 18, 2025. The milestone highlights a urology-led, MRI-guided, incision-free workflow using the TULSA-PRO system, which offers real-time MRI thermography, autonomous temperature control, and robotically controlled directional ultrasound to ablate prostate tissue while protecting nearby structures.
The announcement notes consistent high-volume experience across whole-gland, focal, BPH and salvage cases, with no procedural blood loss or hospitalization reported and an emphasis on preserved urinary and sexual function.
Profound Medical (NASDAQ:PROF) ha annunciato che The Hong Center Scottsdale, guidato dal dott. Y. Mark Hong, ha raggiunto un incredibile traguardo mondiale di 200 procedure TULSA indipendenti eseguite da un urologo senza coinvolgimento del radiologo il 18 novembre 2025. Il traguardo mette in evidenza un flusso di lavoro guidato dall'urologia, MRI-guidato, senza incisioni, utilizzando il sistema TULSA-PRO, che offre termografia MRI in tempo reale, controllo autonomo della temperatura e ultrasuoni direzionali controllati roboticamente per ablare il tessuto prostatico proteggendo le strutture vicine.
L'annuncio segnala un'esperienza ad alto volume costante nei casi di ghiandola intera, focali, BPH e salvage, senza perdita di sangue procedurale o ricovero ospedaliero riportati, con un'enfasi sul mantenimento della funzione urinaria e sessuale.
Profound Medical (NASDAQ:PROF) anunció que The Hong Center Scottsdale, dirigido por el Dr. Y. Mark Hong, alcanzó un hito mundial sin precedentes de 200 procedimientos TULSA independientes realizados por un urólogo sin involucramiento de radiólogo el 18 de noviembre de 2025. El hito destaca un flujo de trabajo guiado por MRI, liderado por urología, sin incisiones, utilizando el sistema TULSA-PRO, que ofrece termografía por MRI en tiempo real, control de temperatura autónomo y ultrasonido direccional controlado por robot para ablación del tejido prostático mientras protege estructuras cercanas.
El comunicado señala experiencia constante de alto volumen en casos de glándula completa, focal, BPH y salvage, sin sangrado procedimental ni hospitalización reportados, y un énfasis en preservar la función urinaria y sexual.
프로파운드 메디컬(나스닥: PROF)은 Dr. Y. Mark Hong이 이끄는 The Hong Center Scottsdale가 의사가 방사선과 의사의 개입 없이 수행한 독립적인 TULSA 시술 200건의 세계 최초 이정표에 도달했다고 발표했습니다. 이 이정표는 TULSA-PRO 시스템을 사용한 MRI 가이드, 절개 없는 urology 주도 워크플로우를 강조하며, 실시간 MRI 열화상, 자율 온도 제어, 로봇 제어 방향성 초음파를 통해 전립선 조직을 제거하되 인접 구조를 보호합니다.
발표는 전체 선과, 국소, BPH 및 구제 사례에서의 일관된 고용량 경험, 시술 출혈과 입원 없음 보고, 요로 및 성 기능의 보존에 중점을 둡니다.
Profound Medical (NASDAQ:PROF) a annoncé que The Hong Center Scottsdale, dirigé par le Dr Y. Mark Hong, a atteint un jalon mondial sans précédent de 200 procédures TULSA indépendantes réalisées par un urologue sans involvement d'un radiologue le 18 novembre 2025. Ce jalon met en lumière un flux de travail dirigé par l'urologie, guidé par l'IRM, sans incision, utilisant le système TULSA-PRO, qui offre une thermographie par IRM en temps réel, un contrôle autonome de la température et des ultrasons directionnels contrôlés par robot pour ablater le tissu prostatique tout en protégeant les structures voisines.
L'annonce fait état d'une expérience à haut débit constante dans les cas de gland intero, focal, BPH et de sauvetage, sans perte de sang peropératoire ni hospitalisation signalée, et met l'accent sur la préservation de la fonction urinaire et sexuelle.
Profound Medical (NASDAQ:PROF) kündigte an, dass The Hong Center Scottsdale, geleitet von Dr. Y. Mark Hong, am 18. November 2025 einen weltweiten Meilenstein 200 unabhängige TULSA-Verfahren erreicht hat, die von einem Urologen ohne Beteiligung eines Radiologen durchgeführt wurden. Der Meilenstein hebt einen urologie-geführten, MRI-gesteuerten, schnittfreien Workflow hervor, der das TULSA-PRO-System verwendet und Echtzeit-MRI-Thermografie, autonomen Temperaturkontrollen und roboter-gesteuerte richtungsabhängige Ultraschallablation bietet, um Prostatagewebe zu zerstören und benachbarte Strukturen zu schützen.
Die Ankündigung erwähnt konsistente Hochvolumen-Erfahrung über Ganzdrüse, fokale, BPH- und Salvage-Fälle, ohne berichteten Blutverlust oder Hospitalisierung, und betont die Erhaltung von Harn- und Sexualfunktion.
Profound Medical (NASDAQ:PROF) أعلنت أن The Hong Center Scottsdale، بقيادة الدكتور Y. Mark Hong، وصل إلى إنجاز عالمي فريد من نوعه بــ 200 إجراء TULSA مستقل قام به طبيب المسالك البولية بدون مشاركة أخصائي الأشعة في 18 نوفمبر 2025. يبرز هذا الإنجاز سير عمل يقوده المسالك البولية، بتوجيه MRI، بدون فتح جراحي باستخدام نظام TULSA-PRO، الذي يوفر تصوير حراري MRI في الوقت الفعلي، والتحكم بدرجة الحرارة بشكل مستقل، وموجات صوتية اتجاهية يتم التحكم فيها آلياً لإتلاف نسيج البروستاتا مع حماية الهياكل القريبة.
تشير الإعلانات إلى خبرة مستمرة عالية الحجم عبر حالات الغدة الكاملة، والعالية، وBPH واستعادة النتائج، بدون فقدان دموي أثناء الإجراء أو إقامة في المستشفى، مع التركيز على الحفاظ على وظيفة التبول والجنس.
- Reached 200 independent TULSA procedures (Nov 18, 2025)
- Demonstrated urologist-only workflow for MRI-guided prostate ablation
- Reported no procedural blood loss or hospitalization in treated cases
- None.
Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy
TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that The Hong Center Scottsdale, led by Dr. Y. Mark Hong of Integrative Urology in Phoenix, Arizona, has achieved a world-first milestone: 200 TULSA Procedures™ performed independently by a urologist, without radiologist involvement. This landmark establishes a new model for delivering MRI-guided prostate therapy.
“Dr. Hong’s longstanding commitment to innovation and compassion for his patients made him a pioneer in bringing the TULSA Procedure, a clinically proven, advanced prostate disease treatment, to patients,” said Profound Medical CEO and Chairman, Arun Menawat. “This 200-procedure milestone is more than a number - it represents the hundreds of men who are now living cancer-free, with preserved quality of life, thanks to his expertise and dedication.”
The TULSA Procedure, performed using Profound’s TULSA-PRO® system, is a significant advancement in prostate care. Instead of surgery or radiation, treatment is performed inside an MRI suite using robotically controlled, directional ultrasound to precisely ablate prostate tissue while protecting surrounding structures. TULSA-PRO is the only AI-powered, MR-guided robotic system for prostate therapy, enabling real-time MRI thermography and autonomous temperature control. This allows physicians to see, monitor and adjust treatment throughout the procedure — delivering personalized therapy with exceptional precision. Often, TULSA Procedures have involved collaboration between urologists and radiologists. Dr. Hong’s independent workflow proves that a urologist alone can safely execute the full procedure — from image planning to ablation — while achieving excellent outcomes.
Among the earliest adopters of the TULSA Procedure, Dr. Hong built one of the world’s first urology-driven practices to offer incision-free prostate care at The Hong Center Scottsdale. Treating patients from Arizona, nationally and internationally, Dr. Hong routinely performs whole-gland, focal, BPH and salvage cases with consistent, high-volume success, achieving exceptional outcomes without procedural blood loss or hospitalization. His experience and expertise have allowed him to treat the most complex of cases with rapid recovery, high cure rates, and preserved urinary and sexual function.
“Having performed hundreds of robotic prostatectomies, I recognized early the potential of the TULSA Procedure to transform prostate cancer treatment,” said Dr. Hong. “Since accountability is the most important factor to improving as an independent surgeon, we are proud of refining the TULSA technique over 200 cases to cure cancer while not causing harm. In my view, TULSA represents the future of prostate disease treatment, one that will ultimately replace radical prostatectomy as a first-line option for prostate cancer.”
Dr. Hong is one of the world’s first board-certified urologists to complete a fellowship in Integrative Medicine. A graduate of Stanford University School of Medicine, Dr. Hong completed his general surgery training at Brigham and Women’s Hospital and his urological surgery residency at Harvard Medical School. His research on prostate cancer and the fear of cancer recurrence remains one of the first works of its kind in the published literature. Dr. Hong completed a robotic and minimally invasive surgery fellowship at George Washington University in Washington, D.C. He has published extensively in nearly every international urological journal.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, any express or implied statements or guidance regarding current or future financial performance; the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma; and the success of Profound’s commercialization strategy and activities for TULSA-PRO®. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Profound, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition, statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and Profound’s ability to execute its operational and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound's Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Susan Thomas
Public Relations
sthomas@profoundmedical.com
T: 619.540.9195
FAQ
What milestone did Profound Medical (PROF) announce on November 18, 2025?
What is the significance of the 200 TULSA procedures for PROF investors?
What clinical benefits did Profound cite for the TULSA Procedure in the announcement?
Does the announcement state that urologists can perform TULSA without radiologist involvement?
Which types of prostate cases has The Hong Center treated with TULSA according to the announcement?
